UNSPSC 51294415: Adatanserin hydrochloride

This classification denotes a serotonin antagonist with the molecular formula C21H31N5O.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 48BX75B06D. The term adatanserin hydrochloride is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule adatanserin hydrochloride under HS 29335995 and SITC 51576. As of Q4 2014, ADATANSERIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Adatanserin hydrochloride bears US NLM identifiers UMLS ID C2700163 and NCI Concept Code C76070.

SMILES: C1CNC(NC1)N2CCN(CC2)CCNC(=O)[C@]34C[C@@H]5C[C@H](C3)CC(C5)C4.CL.

UNSPSC 51294415 Adatanserin hydrochloride is a Commodity code nominally identifying a single pharmaceutical product, but recent state and local solicitations tagged under this code show little activity specifically for adatanserin hydrochloride itself. Instead, the tagged opportunities reflect broader pharmaceutical procurement — naloxone and drug deactivation systems for public health, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products through cooperative purchasing. The code's nominal scope and the work actually being solicited diverge significantly, suggesting either misclassification of these opportunities or limited current demand for adatanserin hydrochloride at the state and local level. When pharmaceutical product codes appear in state and local procurement, issuing bodies typically include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building, with bids due July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program, exploring state-pharmacy-manufacturer relationships outside existing pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, released RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026. The code shows no clear concentration; however, if pharmaceutical procurement at the state and local level is the actual market signal, cooperative purchasing vehicles and state health agencies represent significant entry points.